{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=42&q=type+2+diabetes",
    "query": {
      "q": "type 2 diabetes",
      "page": 42
    },
    "page_size": 10
  },
  "pagination": {
    "page": 42,
    "page_size": 10,
    "total_count": 6123,
    "total_pages": 613,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=43&q=type+2+diabetes&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=41&q=type+2+diabetes&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T16:18:14.677Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04599075",
      "title": "Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes",
        "Pregnancy, High Risk"
      ],
      "interventions": [
        {
          "name": "Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gianna Wilkie",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 70,
      "start_date": "2021-03-15",
      "completion_date": "2023-05-02",
      "has_results": true,
      "last_update_posted_date": "2024-07-08",
      "last_synced_at": "2026-10-17T16:18:14.677Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04599075"
    },
    {
      "nct_id": "NCT01495975",
      "title": "Impact of a Diabetes Transitions Tool Kit on Post-Hospitalization Glycemic Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Diabetes Transitions Tool Kit",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Deborah Wexler, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2011-12",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2016-10-25",
      "last_synced_at": "2026-10-17T16:18:14.677Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01495975"
    },
    {
      "nct_id": "NCT04678557",
      "title": "A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "VC-01 Combination Product",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "ViaCyte",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 31,
      "start_date": "2019-06-25",
      "completion_date": "2021-11-19",
      "has_results": true,
      "last_update_posted_date": "2023-10-18",
      "last_synced_at": "2026-10-17T16:18:14.677Z",
      "location_count": 4,
      "location_summary": "Escondido, California • Walnut Creek, California • Atlanta, Georgia + 1 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04678557"
    },
    {
      "nct_id": "NCT00747175",
      "title": "A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "AZD1656",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 52,
      "start_date": "2008-08",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2010-12-03",
      "last_synced_at": "2026-10-17T16:18:14.677Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00747175"
    },
    {
      "nct_id": "NCT07160257",
      "title": "A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Maridebart cafraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 56,
      "start_date": "2025-08-05",
      "completion_date": "2027-03-04",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-10-17T16:18:14.677Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07160257"
    },
    {
      "nct_id": "NCT00740051",
      "title": "A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Linagliptin",
          "type": "DRUG"
        },
        {
          "name": "Linagliptin Placebo",
          "type": "DRUG"
        },
        {
          "name": "Glimepiride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 227,
      "start_date": "2008-08",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-06-27",
      "last_synced_at": "2026-10-17T16:18:14.677Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Peoria, Arizona • Greenbrae, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Harbor City",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00740051"
    },
    {
      "nct_id": "NCT04321395",
      "title": "Vigabatrin and Insulin Sensitivity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NAFLD",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Vigabatrin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 4,
      "start_date": "2021-08-23",
      "completion_date": "2024-05-15",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-10-17T16:18:14.677Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04321395"
    },
    {
      "nct_id": "NCT04355728",
      "title": "Use of UC-MSCs for COVID-19 Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Corona Virus Infection",
        "ARDS",
        "ARDS, Human",
        "Acute Respiratory Distress Syndrome",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vehicle + Heparin along with best supportive care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Camillo Ricordi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2020-04-25",
      "completion_date": "2020-10-31",
      "has_results": true,
      "last_update_posted_date": "2021-12-06",
      "last_synced_at": "2026-10-17T16:18:14.677Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04355728"
    },
    {
      "nct_id": "NCT01904500",
      "title": "Peri-operative Cefazolin Prophylaxis at Time of Cesarean Delivery in the Obese Gravida",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity",
        "Pregnancy"
      ],
      "interventions": [
        {
          "name": "Pre-operative cefazolin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 26,
      "start_date": "2013-08",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2014-08-18",
      "last_synced_at": "2026-10-17T16:18:14.677Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01904500"
    },
    {
      "nct_id": "NCT05051436",
      "title": "The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pre-diabetes",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Mirabegron 50 MG",
          "type": "DRUG"
        },
        {
          "name": "Tadalafil 10 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Philip Kern",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "35 Years to 65 Years"
      },
      "enrollment_count": 96,
      "start_date": "2021-12-13",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-10-17T16:18:14.677Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05051436"
    }
  ]
}